Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma
This study is ongoing, but not recruiting participants.
Study NCT00791271 Information provided by M.D. Anderson Cancer Center
First Received on November 12, 2008. Last Updated on November 19, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Melanoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interventions listed in this trial
Decitabine
Pegylated Interferon Alpha-2b
Additional drug interventions recognized in this trial
Azacitidine
Interferon Alfa-2a
Interferon Alfa-2b
Interferon-alpha
Interferons
Peginterferon alfa-2b
Reaferon
More general drug interventions related to this trial
Adjuvants, Immunologic
Alcohol Deterrents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Central Nervous System Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Schering-Plough
Eisai Inc.
Back to top of Main Content
